FDA Approves First Oral PCSK9 Drug to Lower LDL

PCSK9 inhibitors are already an established class of cholesterol-lowering drugs. Until now, however, the FDA-approved PCSK9 inhibitors have been injectable.

Lipfendra is taken once a day as a 20-milligram tablet. It works by blocking PCSK9, a protein that causes the liver to remove fewer LDL particles from the bloodstream. Blocking PCSK9 leaves more LDL receptors available on liver cells to clear LDL cholesterol from the blood.

That makes Lipfendra potentially attractive to people who need substantial additional LDL reduction but would prefer a pill to an injection.

The FDA's approval was based primarily on two large randomized, placebo-controlled Phase 3 trials involving a total of 3,207 adults.

In the larger CORALreef Lipids trial, participants had high cholesterol and either established atherosclerotic cardiovascular disease or an increased risk of developing it. They were already receiving their maximum tolerated statin treatment, with or without other cholesterol-lowering medication.

After 24 weeks, Lipfendra produced an average 56% greater reduction in LDL cholesterol than placebo.

In the trial involving people with heterozygous familial hypercholesterolemia, the placebo-adjusted reduction was 59%.

The drug also reduced other blood markers associated with cardiovascular risk, including apolipoprotein B (ApoB) and non-HDL cholesterol.

In the larger trial, the frequency of adverse reactions was similar between people taking Lipfendra and those taking placebo.

In the familial-hypercholesterolemia trial, the side effects occurring more often with Lipfendra were diarrhea and dizziness. Diarrhea occurred in 7% of Lipfendra users versus 2% with placebo, while dizziness occurred in 9% versus 4%. Discontinuation because of adverse reactions was similar between the treatment and placebo groups.

The FDA prescribing information lists no contraindications for Lipfendra.

There is a big distinction between lowering LDL and proving that a particular drug reduces heart attacks and strokes.

Lowering LDL has been shown in previous studies of other therapies to reduce cardiovascular events. But the clinical trials that led to Lipfendra's approval primarily measured its ability to lower LDL and other cholesterol-related markers.

A large cardiovascular-outcomes trial is still underway to determine whether Lipfendra itself reduces major cardiovascular events such as heart attack, ischemic stroke, cardiovascular death and certain procedures.

That study enrolled more than 14,500 people, and its estimated completion is in 2031.

So the evidence is strong that Lipfendra lowers LDL substantially.

It is not yet established from completed outcomes data that Lipfendra reduces heart attacks and strokes.

That distinction is important when interpreting headlines about the new drug.

The FDA-approved dose is one 20-milligram tablet once daily.

There is a catch that is easy to miss: Lipfendra must be taken on an empty stomach in the morning with water, black coffee or plain tea. After taking it, patients must wait at least 30 minutes before eating or drinking anything other than water, black coffee or plain tea. The tablet should be swallowed whole.

The medication can be stored at normal room temperature.

The FDA approval does not mean that everyone with a mildly elevated LDL should start Lipfendra.

It is intended as an additional treatment option for adults whose LDL remains too high despite existing treatment and lifestyle measures. The pivotal trials largely studied people who were already receiving maximally tolerated statin therapy, with some also taking other lipid-lowering medications.

For someone already taking a statin and/or other cholesterol medication, whether Lipfendra makes sense depends on their individual cardiovascular risk, LDL level, treatment history, tolerance of existing drugs and treatment goals.

For older adults who need a large additional reduction in LDL, the important development is not simply that another cholesterol drug exists.

It is that a PCSK9 inhibitor is now available as a daily pill rather than an injection.

That could make this class of LDL-lowering treatment more convenient for some people.

But convenience does not automatically make Lipfendra the right treatment. Existing therapies — including statins, ezetimibe and injectable PCSK9 inhibitors — remain available, and the choice of treatment depends on the individual's circumstances.

The long-term cardiovascular-outcomes results for Lipfendra will also provide important information that is not yet available.

A new once-daily pill can lower LDL substantially without an injection. That could give some people another treatment option when existing medicines aren't enough.

But the drug's ability to lower LDL has been established; whether Lipfendra itself reduces heart attacks and strokes is still being studied.

Lipfendra is a significant new cholesterol-treatment option. In clinical trials, it lowered LDL by roughly 56–59% compared with placebo, including in people already receiving other cholesterol-lowering treatment.

Its biggest difference from existing PCSK9 inhibitors is simple: you take it as a pill instead of an injection.

But there is an important reason not to overinterpret the announcement. The FDA approval establishes that Lipfendra effectively lowers LDL. The large trial designed to determine whether it also reduces heart attacks, strokes and other major cardiovascular events is still underway.

For anyone considering it, the relevant question isn't simply “Does this drug lower LDL?” It does.

The more personal question is whether the additional LDL reduction and convenience make sense compared with the other treatments already available.